VTEX Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw resilient profitability and margin expansion despite macro headwinds and elongated sales cycles, with AI, global expansion, B2B, and retail media driving growth. Guidance for 2026 targets mid to high single-digit FX-neutral subscription revenue growth and continued investment in AI and R&D.
-
Q3 2025 delivered strong profit growth, margin expansion, and robust cash flow, driven by AI-powered efficiency and international B2B momentum. Despite LATAM macro headwinds, guidance remains positive, with continued investment in AI, B2B, and Retail Media.
-
Q2 2025 saw resilient growth with GMV up 9% and subscription revenue up 6% in USD, despite headwinds in Argentina and Brazil. Margins expanded, guidance for operating income and free cash flow was raised, and global expansion—especially in the U.S. and Europe—accelerated.
-
Q1 2025 saw 15% FX-neutral subscription revenue growth, margin expansion, and strong free cash flow. New customer wins, the Newtail acquisition, and disciplined R&D investment support a positive outlook, with full-year FX-neutral subscription revenue growth targeted at 14%-17%.
Fiscal Year 2024
-
2024 saw robust enterprise growth, product innovation, and margin expansion, though Q4 revenue lagged due to FX and Brazil's consumer softness. Guidance for 2025 targets 14%-17% FX neutral subscription revenue growth, with continued focus on operational leverage and new product adoption.
-
Q3 2024 saw double-digit revenue and subscription growth, margin expansion, and strong free cash flow, driven by new customer wins, platform innovation, and a maturing ecosystem. Guidance for Q4 and full-year 2024 remains robust, with continued focus on profitable growth and operational efficiency.
-
Q2 2024 delivered strong FX neutral growth in GMV and revenue, with significant margin expansion and positive free cash flow. Guidance for full-year revenue and profitability was raised, supported by robust customer performance, global expansion, and operational efficiency.